What Takeda is Getting for Its Money in Its Latest $100 Million Deal With GammaDelta Therapeutics

Japanese biotechnology giant Takeda recently announced the latest in a string of deals that have seen it take relatively large stakes in the future of tiny, development stage biotechnology companies. Each of these recent announcements included a clause through which Takeda retains the right to acquire the companies in question if it chooses to do so once the initial partnership matures towards completion, and the latest is no different. What is slightly different about this one, however, is what the company is getting for its money. The science on which said tiny biotech entity is working is relatively undeveloped in the space, and this makes it difficult to form an opinion (from a nonscientific investor's standpoint) as to what value it might bring for Takeda going forward.